Trial Profile
A study of combination of Farnesoid X receptor (FXR) agonists and cenicriviroc (CVC) for the treatment of non-alcoholic steatohepatitis (NASH)
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 21 Apr 2017
Price :
$35
*
At a glance
- Drugs Cenicriviroc (Primary) ; Farnesoid X-activated receptor agonists (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; Therapeutic Use
- 21 Apr 2017 New trial record